Neuroblastoma is one of the most common solid tumors in childhood. With the aim of developing a targeting vector for neuroblastoma, we cloned and characterized an enhancer in the 5 0 -flanking regions of the MASH1 gene by a random-trap method from a 36 kb cosmid DNA. The enhancer-containing clone was identified by the expression of GFP when transfected into neuroblastoma cell lines. The enhancer-luciferase activity is higher in neuroblastoma cell lines, IMR32, BE2 and SH-SY5Y, compared with those in non-neuroblastoma cell lines, U1242 glioma, N417 small cell lung cancer and EOMA hemangioma. The core enhancer was determined within a 0.2 kb fragment, yielding three-to fourfold higher activity than that of the MASH1 promoter alone in IMR32 and BE2. This area possesses GATA-and CREB-binding sites, as well as the E-box. EMSA on this area demonstrated that CREB/ATF could bind the DNA. Chromatin immunoprecipitation assay revealed that N-myc, CREB, and co-activators CBP and PCAF, but not HDAC1, are bound to the core enhancer at the same time as the co-activators and N-myc bind to the promoter. This supports the idea that the commonly overexpressed genes HASH1 and N-myc are regulated in concert, confirming their importance as prognostic markers or targets for therapy.
Introduction
In the developing nervous system a genetic program specifies the correct order for genes to be activated, both spatially and temporally. Proneural genes encode basic helix-loop-helix (bHLH) transcription factors, essential in early neurogenesis. 1 Vertebrate homologs of proneural genes are known as the atonal-related neurogenins 2 and the achaete-scute-related MASH1.
3 MASH1 is the best characterized member of the vertebrate proneural genes, and is sufficient to induce differentiation of neurons. 2 MASH1 is expressed in neural crest cells after they colonize the anlage of the sympathetic ganglia, adrenal medulla, subsets of enteric precursors, and in parasympathetic neurons which surround major blood vessels. 4 
MASH1
À/À mice have severe developmental defects in sympathetic ganglia 5 and chromaffin cells, 6 indicating its importance for the maturating autonomic nervous system. MASH1 is also widely expressed in the early stages of CNS development, 1 and a CNS-specific enhancer has been isolated and shown to control MASH1 expression. 7 It is assumed that there exist control elements in this gene, which are specific for the peripheral autonomic nervous system. Isolating such elements may enable us to track the regulation of gene expression as stem cells differentiate into autonomic neurons. These elements could also be used to target a therapy-gene expression in various neural crest-derived tumors.
One example is neuroblastoma -one of the most common extracranial solid tumors in childhood, being derived from sympathetic derivatives of neural crest cells. Many primary neuroblastoma cells and cell lines possess the immature phenotype, and express high levels of the human homolog of the MASH1, that is HASH1. 8 Using an enhancer sequence of MASH1 gene, which is specifically active in the sympathetic neurons, allows the targeting of a therapy gene in neuroblastoma expressing HASH1. The MASH1-promoter alone has been shown to provide cell type-specific expression and cytotoxic effects of the therapy gene (Escherichia coli purine nucleoside phosphorylase) in neuroblastoma cell lines. 9 This approach should increase the efficacy of in vivo tumorspecific expression of exogenous gene in tumor cells without giving unwanted effects on normal tissues. 10 In most reported gene therapy trials, therapy genes are transduced by viral enhancer/promoters, often giving rise to strong expression but lacking in tissue-specificity.
Nevertheless, other studies have demonstrated specific and long-lasting expression of a therapy gene in target cells, under the control of tissue-specific enhancer/ promoters.
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In the present study, we attempt to isolate specific cisacting elements operating in HASH1-expressing neuroblastoma cell lines. We isolate and characterize an enhancer located upstream of the MASH1-coding sequence, from a 36 kb cosmid (McosI) containing both upstream and downstream elements of the entire MASH1 gene. 11 We then compare its activity in various neuroblastoma and non-neuroblastoma cell lines. The transcription factors binding to this region, CREB and N-myc, are identified by EMSA and Chromatin Immunoprecipitation (Chip) assays.
Materials and methods

Cell cultures
The human neuroblastoma cell lines SH-SY5Y, BE2, IMR32 and mouse neuroblastoma C1300 were cultured, as described previously.
9 IMR32, BE2 and C1300 contain amplified N-myc and show increased HASH1 or MASH1 expression. The small-cell lung cancer (SCLC) NIH-N417, the breast cancer MCF7, and the mouse hemangioma EOMA lines were cultured in DMEM, and the malignant glioma U1242 line was cultured in a-MEM.
Preparation of the enhancer-cloning vector An enhancer trap vector was designed as described elsewhere. 11 The vector consists of Green Fluorescent Protein (GFP) reporter gene driven by 0.3 kb MASH1 gene promoter (base 2-386 including 314 bp upstream of the transcription start site and 73 bp of the 5 0 untranslated region, accession number U68534). The length of the promoter was determined by our in vitro data obtained after comparison with activities of various length of the promoter cloned into pGL3b luciferase vector (Promega). 9 The multiple cloning sites for DNA fragment insertion were placed upstream of the promoter. As negative background controls were used p0.3pGFP, containing only the 0.3 kb MASH1 promoter, and a basic vector.
Cloning of enhancer that is active in neuroblastoma cell line IMR32 For enhancer screening, a library was prepared by inserting into the trap vector partially digested DNA fragments from an approximately 36 kb MASH1 cosmid (pMI cos) clone, provided by Dr J Johnson.
12 Briefly, we cleaved the cosmid DNA to generate partially digested products, which then were cloned into a vector to make a library. The digested cosmid DNA containing any enhancer can be identified by the expression of GFP when transfected into IMR32 cells. Eight plates of colonies in 7 Â 7 matrix were screened in three rounds, and clones with strongest expression were subcloned into pGL3 vector for quantitative analysis in both neuroblastoma and non-neuroblastoma cell lines. Mapping of enhancer clones was performed by the appropriate restriction enzymes and Southern transfer, using several probes made from the positive clone.
Promoter reporter assay Cells were seeded in 24-well plates at a density of 2 Â 10 4 cells/well in 10% serum. The following day, the cells were transiently transfected with 100 fmole of each enhancer construct using 60 ml Fugene6 (Roche, Mannheim, Germany) or Lipofectamine (Invitrogen, Carlsbad, CA, USA) according to the vendor's instructions. After 48 h cells were lysed with 100 ml/well of a reporter lysis buffer (Promega, Madison, WI, USA) and luciferase activity was measured. Standardization was done by co-transfection with b-galactosidase reporter plasmid and results were normalized to the activity. The values were presented as means and s.e. of three independent transfections, each carried out in triplicate. Comparisons using t-tests were made between the MASH1 promoter alone and the values obtained by different enhancer constructs within the respective cell lines. Differences were considered significant at *Pp0.05, **Pp0.01 or ***Pp0.001. Only increased values were marked.
Electrophoresis mobility shift assay
The 55-mer oligonucleotide (oligo) and the 82 bp HinfI fragment in the core enhancer HindIII/EcoRV were used as probes ( Figure 6 ). The sequences of the oligos that were used for competition are: GATA2/3, 5
0 . The probes were end-labeled with g-32 P-ATP (Amersham, Buckinghamshire, UK) and T4 polynucleotide kinase and then purified, and nuclear extracts (NE) were made from BE2, IMR, MCF-7 cells. Electrophoresis mobility shift assay (EMSA) was performed as described previously. 13 For the competition experiments or supershift assay, preincubation was performed in the presence of 10-and 100-times unlabeled competitor oligo.
Chromatin immunoprecipitation assay
Chip assays were performed as described previously 14 by using the mouse neuroblastoma cell line C1300. The antibodies directed against CREB, CBP, PCAF, USF1 and N-myc, or mouse IgG were purchased from Santa Cruz Biotechnology, Santa Cruz, CA, USA. All the antibodies were shown to work adequately for Chip assay. Immune complexes were collected by incubation with protein G-agarose (Santa Cruz) for 1 h at 41C. Aliquots of the purified DNA were diluted and analyzed by PCR with the appropriate primer pairs. The primers used for the MASH1 enhancer and promoter were 5 0 -GGGATATCTCGTTCTTGCCTTCAC-3 0 and 5 0 -CT ACAGGGTAATCTTGATTAAGCT-3 0 as well as 5 0 -TT ATTCAGCCGGGAGTCCGG-3 0 and 5 0 -TGCGGCCG CCTTTTCAATGG-3 0 . The primers for a coding region used for the control were described previously. 9 Amplification was performed for a predetermined optimal number of cycles. PCR products were separated by electrophoresis on 2% agarose gels, and stained with ethidium bromide.
Results
Cloning and characterization of MASH1 enhancer
The cloning method has been described in Watt et al.
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Restriction fragments randomly cleaved from the pMI cos were inserted in the pMASH0.3pEnTrap vector in the upstream of the MASH1 promoter and the GFP reporter gene. We screened their activities by counting GFP expressing cells at 12, 24 and 48 h after transfection of the clones inserted in the trap vector in IMR32 cell line. Three rounds of screenings resulted in isolation of 11 positive clones, and the best clone was chosen for further analysis. In order to map the trapped fragment in this clone, BamHI fragments from pMIcos was subcloned and a restriction map was made. In addition, patterns of restriction digestion were compared between the enhancer fragments cloned into Bluescript. To determine where the cloned enhancer lies within the genome, Southern transfer analysis with a variety of restriction enzymes was conducted with probes made from the positive clone indicated in Figure 1 .
The most active clone, #4en, was approximately 2 kb long and mapped by hybridization to the 5 0 flanking region. Position of the clone was found to be upstream within 4 kb proximity of the JIB, 7 as depicted in Figure 1 , being not in the region where the CNS-specific enhancer was identified. 7 The 2 kb enhancer containing NcoI/ EcoRI fragment was sequenced. The sequence was found to lie on Ch10 at location around 42.7 kb upstream of the ATG initiation site of Mus musculus MASH1 gene. The active 0.5 kb HindIII/HindIII site carried a spliced stretch of totally 243 bp homology with Rattus norvegicus sequence at the corresponding area on Ch7. However, only a few stretches of 20-30 bp homologous sequences were found on human Ch12 where HASH1 resides.
Enhancer activity of deletion mutants of MASH1 #4 enhancer in various cell lines
We optimized the activity of enhancers by screening deletion constructs to find a shortest but sufficient length of the fragment giving a strong expression of the reporter gene. Various sizes of fragments from the #4en were prepared by restriction mapping, and cloned into the p0.3pGL3 plasmid containing the 0.3 kb MASH1 promoter upstream of the luciferase gene. They were analyzed by using reporter assays by transfecting the constructs into the IMR32 and BE2 neuroblastoma cell lines ( Figure 2 ). These fragments were cloned in both sense and antisense directions to the promoter (Figure 2a ). The strongest activity was obtained with the XbaI/EcoRI (clone 12; Figure 2b ). The deletion constructs devoid of the HindIII/HindIII fragment, NcoI/EcoRI D(H3-H3) (cl. 9) and PstI/HindIII (cl. 8), resulted in a dramatic decrease, indicating the presence of an active site in the HindIII/HindIII. The antisense XbaI/ EcoRI (cl. 12) exhibited a stronger activity than the senseoriented cl. 11 and 14. Further deletion constructs were made based on this sequence as shown in Figure 3a , and their activities were compared ( Figure 3b) .
Four of the deletion constructs shown in Figure 3 demonstrated higher activities: the XbaI/EcoRI (cl. 12), its deletion mutants (cl. 18, 21) , and the HindIII/HindIII (cl. 24). It is obvious that the core enhancer activity resides in the 0.5 kb HindIII/HindIII fragment. These constructs yielded similar and stable activities in both IMR32 and BE2 cell lines. This 0.5 kb fragment was shown to contain a stronger enhancer activity when the sequence was ligated in the antisense orientation to the promoter. In BE2 cells, the activity of cl. 12, 18, 21 and 24 was about threefold higher than that of the promoter alone, p0.3GL3.
In order to ensure the cell-type specificity, we compared activity of the enhancer constructs in several cell lines, including the SH-SY5Y, a relatively differentiated neuroblastoma cell line without N-myc amplification, as well as the neuroendocrine SCLC N417. They were compared with the glioma cell line, U1242, and the hemangioma cell line, EOMA. As shown in Figure 4 , the promoter p0.3pGL3b showed slight but clearly higher activity in IMR32 and SH-SY5Y compared with other three nonneuroblastoma cell lines. This confirms that the promoter also has some cell-type specific activity as reported. 9 By contrast, the SV40 promoter (cl. 30) did not show any MASH1-enhancer active in neuroblastoma F Watt et al neuroblastoma-specificity. Again, the 0.5 kb antisense HindIII/HindIII construct yielded the highest activity in IMR32 (cl. 24). The p1.6en0.3pGL3 (cl. 10) yielded about the same activity as the MASH1 promoter alone, however, the activity in SH-SY5Y was lower. The N417 SCLC showed a significantly higher activity of the enhancer (cl. 24, 28), compared with that of the promoter alone.
With all the constructs examined, the strongest response was seen with the HindIII/HindIII in IMR32, more than twofold of the activity seen in other cell lines. A weak enhancer activity was also found in the neuroendocrine cell line N417 (cl. 24). Cell lines lacking the HASH1 expression, U1242 and EOMA, showed no clear specificity to the MASH1 promoter/enhancer. The MASH1 promoter activity was comparable in both IMR32 and SH-SY5Y but the enhancer activity was not appreciable in SH-SY5Y.
The previously reported 1158-bp 5 0 -MASH1 CNS enhancer 7 was inserted upstream of the 0.3 bp MASH1 promoter in the pGL3 vector (CNSen) and the luciferase activity was measured (Figure 4 , cl. 26). The deletion of the 118 bp sequence at the 3 0 -end of this CNS enhancer (CNS/PNSen) was tested in the same manner ( Figure 4 , cl 27). This has been shown to give a broader expression in the NS. 7 None of these constructs showed any clear activity in the tested cell lines when compared with the 0.3 kb MASH promoter vector.
Core enhancer sequence
In order to identify the most active core enhancer area, further deletion mutants were made in the p1.2enXbaI/ EcoRI containing the 0.5 kb HindIII/HindIII and the activities examined in IMR32 and BE2 (Figure 5a ). In the proximity of the 3 0 HindIII toward the downstream EcoRI, there is a GAGA-stretch, which has been shown to link an enhancer to its cognate promoter through POZdomain-mediated GAGA oligomerization. 15 As shown in Figure 5b , the deletion of SacI/BstXI fragment, containing the GAGA-stretch (cl. 18) or a slightly larger deletion of PmI/BstXI (cl. 21) containing also an E-box, did not change the activity of the original XbaI/EcoRI (cl. 12), and the activity is comparable to the 0. Relative Luc Activities * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * MASH1-enhancer active in neuroblastoma F Watt et al a deletion of the middle segment EcoRV/KpnI reduced the repression seen in the sense orientation. The 3 0 deletion constructs 0.2 kb HindIII/EcoRV (cl. 34) and 0.3 kb HindIII/KpnI (cl. 33), both in the sense orientation, showed slightly higher activities than the 0.5 kb antisense HindIII/HindIII (cl. 23, 24) . In contrast, the 3 0 part of the HindIII/HindIII, the 0.2 kb KpnI/HindIII (cl. 36) as well as the 0.3 kb EcoRV/HindIII (cl. 35), both in the antisense orientation, yielding a lower activity than the promoter alone. Taken together, the 0.2 kb HindIII/EcoRV is sufficient for the activity, independent of its orientation.
Transcription factors binding the core enhancer
Analysis of the various constructs indicates that the enhancer core is located around the 0.2 kb HindIII/ EcoRV area. Transcription binding motifs found in the 0.5 kb HindIII/HindIII is schematically depicted in Figure 6a , containing several binding sites for AP-1, GATA2/3, Nkx-2, Oct1, CREB/CRE-BP, BMP responsive elements and USF.
In order to determine which proteins bind to the enhancer, two probes were made around the recognition sites for the above-mentioned transcription factors. One of the probes is a 55-mer oligo containing putative binding sites for CREB, CRE-BP, GATA2/3, AP1, AP2, ATF-EIIa and NF-1 (Figure 6a ). The EMSA with NE of BE2 showed two major bands, one upper weak and the lower stronger one (Figure 6b 
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F Watt et al NF1 consensus oligos was able to diminish any of the bands. ATF-EIIa-oligo completely blocked the upper band, and the lower band was decreased, yet still visible. CREB-oligo abrogated the upper band and the middle band, but not the lowest band (Figure 6c ). The presence of these transcription factors in the NE was confirmed by using consensus oligos as probes. Although these probes are smaller than the 55-mer probe a similar binding pattern shown by the 55-mer probe was detected with the consensus probes of CREB and ATFEIIa, suggesting their identities. Furthermore, EMSA was performed to examine whether the binding protein is CREB or not, by competition with the consensus or a mutated CREB oligo. The upper two bands were competed out at the similar efficiency with the self and the CREB consensus oligos but not with the mutated one. When the CREB consensus oligo was used as a probe, a similar pattern was seen, which again disappeared by adding the consensus but not the mutated oligo. As expected, a labeled mutated CREB oligo did not build The each consensus oligo used for blocking was labeled and incubated with the NE for EMSA (lane 9-14). (c) The 55-mer oligo was labeled and incubated with 100 Â self oligo, 10 Â ( þ ), 100 Â ( þ þ ) of CREB consensus oligo or 10 Â of a mutated CREB oligo with NE. The CREB consensus and the mutated CREB oligos were labeled and used for EMSA alone or with CREB or the mutated consensus oligo.
MASH1-enhancer active in neuroblastoma F Watt et al any complex. Repeated EMSA with NE from IMR32 showed similar results as compared with BE2 (results not shown).
Another probe used was a HinfI fragment that overlaps with the 3 0 half of the 55-mer probe extending to the further downstream, including an E-box but not the CREB site (Figure 6a) . NE from BE2 and IMR32 as well as the breast cancer cell line MCF7 were used. A series of EMSA indicates that USF is present in all the cell lines examined, and the protein binding the enhancer probe is not a single protein (not shown). The DNA-binding protein complex seems to contain different proteins in the neuroblastoma cell lines from those in MCF7 (not shown).
In order to see whether the above-mentioned transcription factors would bind to the core enhancer region in vivo, Chip assays were performed with mouse neuroblastoma C1300 cells. As expected, CREB and the coactivator CBP were found to bind chromatin within the enhancer region. In addition, binding of N-myc but not USF to chromatin was evident ( Figure 7) . The coactivator PCAF was also detected to bind, but the corepressor HDAC1 did not. Interestingly, N-myc as well as both of the co-activators bound the 0.3 kb MASH1 promoter region. No binding was seen with any of the antibodies on a MASH1 coding area. These results confirm an active status of the enhancer chromatin in this cell line. Immunoblotting confirmed that CREB is expressed in SHSY5Y and BE2 cells, and N-myc is overexpressed in IMR32, BE2 and C1300 cells (not shown). 16 
Discussion
Cell-type specific enhancers have been widely applied for various purposes, that is, to create transgenic or knockout mice targeted in a specific cell type, and to mark a lineagespecific differentiation of stem cells or progenitors. They can be employed clinically to obtain a tissue-specific gene expression for diagnosis and therapy in patients with deficiencies of vital proteins, or tumors that must be eliminated. This can be achieved by an optimal combination of enhancers/promoters placed upstream of a marker or therapy gene. Such an approach could be used for advanced neuroblastomas that are resistant against conventional therapies, and which presently lack effective therapy.
The human homolog of MASH1, HASH1, is expressed in 66% of primary neuroblastomas 17 and in six out of six neuroblastoma cell lines derived from the sympathetic nervous system. 18 These reports also described that HASH1 transcripts became downregulated in several cell lines during induced differentiation. HASH1 is also expressed in other neuronal and neuroendocrine malignancies such as SCLC and medullary thyroid carcinoma, which are highly metastatic tumors with lethal outcomes. 19 Many other neuroendocrine tumors, such as pheochromocytomas and carcinoids, also express HASH1, 19, 20 while the expression is completely absent in non-neuroendocrine tumor cells or adult normal cells. 19, 21 In these neuroendocrine tumors, HASH1 expression is strongly associated with the neuroendocrine properties. 20 An SCLC cell line, N417, yielded a weak but specific enhancer activity in our study. Whether this enhancer can be also used for a targeted gene therapy of SCLC and other neuroendocrine tumors deserves further study.
We used the murine MASH1 0.3 kb promoter to trap its enhancer. This promoter is sufficient to yield a promoter activity when compared with longer promoters, that is, 0.8 and 1.2 kb promoters upstream of the initiation site in the 5 0 -flanking region. 9 The smaller the regulatory region, the easier it is to obtain a flexible therapy gene cassette. It has been reported that this 0.3 kb promoter, including repeated Sp1-consensus sites, is conserved in mouse and human. 19, 22 In addition, the a-HDAC1 a-PCAF a-CBP a-N-myc Figure 7 Chip assay over the area covering the MASH1 core enhancer and promoter. Chromatin extracted from C1300 cells was immunoprecipitated with antibodies against CREB, USF, HDAC1, PCAF, CBP, N-myc or mouse IgG. DNA was purified and analyzed by PCR together with whole cell lysate (input), using primers specific for the enhancer and promoter of MASH1 with the coding region as a negative control.
MASH1-enhancer active in neuroblastoma F Watt et al proximal region between positions À305 and À234 is a binding site for HES1, considered to be the tissue-specific repressor. 19 In fact, HES1 overexpression directly represses HASH1 expression, and this regulatory mechanism has been shown to be involved in the normal development of the nervous system. 22, 23 For gene targeting, inclusion of this sequence could add the tissue specificity by excluding non-neural tissues that contain a high level of HES1. Hence, it can contribute to the specificity in neuronal cells over other cell types. Recently, it has been reported that HES1 together with the corepressor TLE1 is bound to the MASH1-promoter and silences it. HES1 can be phosphorylated by calmodulin kinase IId, forming a complex with a co-activator on the promoter in order to act as an activator in proneural cells. 24 Thus, HES1 bound on this promoter can alter its activity depending on the stimulus, providing a possibility for broader cell type-specific responses.
We identified a MASH1 enhancer/promoter combination that provided a tissue-specific expression of a reporter gene. Furthermore, the best MASH1 enhancer/ promoter combination containing the core enhancer region was more active in N-myc amplified neuroblastoma cell lines, correlating with the HASH expression. This suggests that normal neuroendocrine cells and tissues may not be affected in vivo, ensuring the safety of the gene therapy using this targeting cassette.
The core enhancer region was narrowed to 0.2 kb of the enhancer, and the transcription factors binding to this region were examined in order to understand the mechanism how the MASH1 enhancer confers it activity. The factors that were found to bind the sequence were CREB/ATF2. However, other factors that were thought to bind to this area, AP1, AP2 or GATA2/3, fail to do so. Members of the CREB/CREM/ATF family of transcription factors either enhance or repress transcription after binding to the cAMP response elements (CREs) of numerous genes. 25 CREB-mediated gene expression is particularly important in the nervous system, regulating neuronal survival, memory, biological clock and synaptogenesis. The broad spectrum of its activity might depend on the fact that CREB target genes frequently encode transcription factors such as Egr1, Nurr1 and herein MASH1. ATF is considered to be a preferentially expressed CREB family member in the nervous system. ATF is induced during neuronal differentiation, and when neuronal cells are injured ATF protects the cells by inducing various genes. 26 However, overexpression of CREB but not of ATF upregulated the MASH1 enhancer/promoter activity in BE2 cells (result not shown). The co-activator CBP was also found on the chromatin, binding CREB to enhance the transcription activity.
Slightly downstream of the CREB-binding site there is an E-box, where a certain protein was found to bind in our EMSA. This protein was present in the NE from the two neuroblastoma cell lines, but not that of the MCF7 breast cancer cell line (results not shown). Chip assay in C1300 cells revealed that N-Myc was strongly bound to this enhancer chromatin and also the proximal promoter region. A closer inspection of the promoter region revealed a non-canonical Myc-binding motif CACGCG, located at À243 from the transcription start site 27 and being distal to the C-site known to bind HES. Even closer to the initiation site there are CpG islands, possibly facilitating the binding of N-myc to the CACGCG motif. 9, 28 However, transfection of N-myc into the neuroblastoma cell lines could not augment the MASH1 enhancer-promoter luciferase activity (result not shown). This unresponsiveness might be due to the abundant endogenous N-myc expressed in neuroblastoma. These cell lines constitutively express HASH1, and N-myc is one of the best markers associating with the aggressive progression of advanced neuroblastoma. 29 The activity of this enhancer therefore might serve as a good indicator for endogenous expression of both HASH1 and N-myc proteins in neuroblastoma cells. By analogy, Yazawa et al. 30 demonstrated that N-myc regulates HASH1, and both are bound to the E-box in class II transactivator, which is strongly downregulated in SCLC and neuroblastoma. It is thus possible that these transcription factors, being overexpressed and/or amplified specifically in such neuroendocrine tumors, are functional for maintenance of their phenotypes.
Johnson et al. 7 previously cloned an enhancer of MASH1 by using a transgenic model, which confers CNS-specific MASH1 expression. As expected, this enhancer could not show any activity in the cell lines derived from the PNS, which we tested here. The redundancy of MASH1 enhancers spread in this gene is concordant with its transient but broad expression in the autonomic nervous system in the PNS, as well as in neuronal progenitor cells in the CNS.
In conclusion, we have cloned and characterized a MASH1 enhancer that is active in neuroblastoma cell lines. This enhancer might be employed to target a therapy-gene expression in neuroblastoma and other neural crest-derived tumors in vivo tumor models.
